Maze Therapeutics (NASDAQ:MAZE – Get Free Report) issued its earnings results on Monday. The company reported ($0.79) earnings per share for the quarter, missing the consensus estimate of ($0.78) by ($0.01), FiscalAI reports.
Maze Therapeutics Stock Up 4.8%
MAZE stock traded up $1.72 during midday trading on Wednesday, reaching $37.16. The company had a trading volume of 189,280 shares, compared to its average volume of 672,065. The company has a 50 day moving average of $28.12 and a two-hundred day moving average of $31.67. The company has a market capitalization of $2.06 billion, a P/E ratio of -14.00 and a beta of 2.04. Maze Therapeutics has a 1 year low of $21.95 and a 1 year high of $53.65. The company has a current ratio of 18.31, a quick ratio of 18.31 and a debt-to-equity ratio of 0.09.
Insider Buying and Selling at Maze Therapeutics
In other Maze Therapeutics news, insider Courtney Phillips sold 2,012 shares of the company’s stock in a transaction dated Thursday, September 3rd. The shares were sold at an average price of $26.01, for a total transaction of $52,332.12. Following the completion of the sale, the insider directly owned 7,007 shares in the company, valued at $182,252.07. This represents a 22.31% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Jason V. Coloma sold 34,501 shares of the business’s stock in a transaction on Thursday, October 1st. The stock was sold at an average price of $27.02, for a total transaction of $932,217.02. Following the transaction, the chief executive officer directly owned 15,558 shares in the company, valued at $420,377.16. This trade represents a 68.92% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 192,991 shares of company stock valued at $5,187,559 over the last three months. 5.30% of the stock is owned by insiders.
Hedge Funds Weigh In On Maze Therapeutics
Hedge funds and other institutional investors have recently made changes to their positions in the business. TRV GP IV LLC acquired a new stake in shares of Maze Therapeutics in the 2nd quarter valued at $133,502,907. ARCH Venture Management LLC acquired a new stake in shares of Maze Therapeutics during the second quarter worth about $122,983,582. BlackRock Inc. acquired a new stake in shares of Maze Therapeutics during the second quarter worth $104,525,000. Jupiter Topco LLC bought a new stake in Maze Therapeutics in the 2nd quarter valued at approximately $101,764,000. Finally, Alphabet Inc. acquired a new stake in shares of Maze Therapeutics during the 2nd quarter worth about $41,435,000.
Analysts Set New Price Targets
A number of equities research analysts have weighed in on the company. TD Cowen upgraded Maze Therapeutics to a “strong-buy” rating in a research note on Monday, August 24th. HC Wainwright reiterated a “buy” rating and set a $110.00 target price on shares of Maze Therapeutics in a research note on Thursday, September 24th. BTIG Research reaffirmed a “buy” rating and set a $46.00 price objective on shares of Maze Therapeutics in a research report on Tuesday, September 22nd. Citigroup began coverage on shares of Maze Therapeutics in a research note on Wednesday, September 23rd. They set a “buy” rating and a $50.00 price objective on the stock. Finally, Wall Street Zen cut shares of Maze Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, August 15th. Three analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Maze Therapeutics has a consensus rating of “Buy” and a consensus price target of $63.91.
Read Our Latest Stock Analysis on MAZE
About Maze Therapeutics
Maze Therapeutics is a clinical-stage biotechnology company developing precision medicines for people with serious diseases. Its research uses human genetics and functional genomics to identify disease-related biological pathways and potential drug targets. The company’s Maze Compass platform is designed to connect genetic insights with biological research to guide drug discovery and development. Its investigational programs have included approaches for APOL1-mediated kidney disease and Pompe disease; these are not marketed treatments.
Read More
- Five stocks we like better than Maze Therapeutics
- Can Constellation Energy’s Contracts Power a Stock Rebound?
- Why Apple Stock Looks Like a Safe Haven After the Midterms
- IonQ Raised the Bar, But 3 Quantum Rivals Face Tough Questions
- On Holding’s Sell-Off Overlooks a Key Part of Its Earnings Story
Receive News & Ratings for Maze Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Maze Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
